Clinical Trial Update: Retreatment With CTL019/CTL119 [Phase 1]

View source ↗

Summary

Phase 1 trial update regarding retreatment with CTL019/CTL119 for B-cell lymphoma; the study status is NOT_YET_RECRUITING.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma B-cell

Drugs mentioned

• CTL019 (tisagenlecleucel)
• CTL119

Snippet

Sponsor: University of Pennsylvania | Conditions: Lymphoma, B-Cell | Phase 1 | Status: NOT_YET_RECRUITING